Clinical Outcomes of Included Patients
| Clinical outcome | Good responder (n = 13) | Poor responder (n = 12) | P |
|---|---|---|---|
| Number of 223Ra injections | NA | ||
| 1–3 | 0 (0%) | 7 (58%) | |
| 4–5 | 0 (0%) | 5 (42%) | |
| 6 | 13 (100%) | 0 (0%) | |
| FFS (wk) | 25.9 (25.0–35.1) | 11.7 (10.0–17.3) | <0.001* |
| Reason for treatment failure | 0.068† | ||
| Progression of bone disease | 9 (69%) | 3 (25%) | |
| Development of extraosseous metastases, with/without progression of bone disease | 4 (31%) | 8 (67%) | |
| Unspecified progression of disease | 0 (0%) | 1 (8%) | |
| Overall survival (wk) | 91.0 (67.1–102.3) | 27.0 (16.4–48.0) | 0.004* |
| ALP response | 8 (62%) | 5 (42%) | 0.434† |
| PSA response | 0 (0%) | 2 (17%) | 0.220† |
| Time to ALP progression (wk) | 39.9 (28.7–NR) | NA | NA |
| Time to PSA progression (wk) | 15.0 (14.7–15.0) | 16.0 (13.9–NA) | 0.114* |
↵* Log-rank test.
↵† χ2 test.
NA = not applicable; PSA = prostate-specific antigen; NR = not reached.
Two patients discontinued treatment because of toxicity and were not included in table. Qualitative data are number and percentage; continuous data are median and IQR. ALP and prostate-specific antigen response was defined as ≤–30% change from baseline.